Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

Korábbi kezelés

• Use of a GLP-1 agonist or DPP4 inhibitor medication
• Chronic steroid use or use within the last 30 days

Más betegség

• The study will exclude volunteers with any significant medical conditions that may interfere with study participation, data interpretation, or pose safety risk(s) to the subject.
• Recent hospitalization or acute illness such as infection within the past two weeks
• Use of oral diabetes agents other than metformin unless matched with controls
• Type 1 diabetes
• Significant liver disease including liver enzymes >3 x upper limit of normal range
• Significant cardiac disease such as heart transplantation
• Significant gastrointestinal conditions that may interfere with drug absorption or GLP-1 release including bariatric surgery
• Significant hematologic disease such as hematocrit <35%
• Severe pulmonary disease
• Severe neurologic or psychiatric disease

Laborértékek

• Renal dysfunction defined as eGFR< 50mL/min/1.73m2

Egyéb

• Pregnancy
• Use of insulin
• Use of chronic anticoagulation
• Inability to comprehend study procedures

• Participant of the Penn Medicine Biobank who is willing to be recontacted to participate in future research.
• Cases are defined as adults 18-70 years with likely decreased DPP4.
• Controls are defined as adults who are matched to cases by: age, gender, race, BMI, hypertension status, diabetes status, renal function, and medication use that may affect outcomes of interest.